Procept Biorobotics CORP 10-Q quarterly reports

PROCEPT BioRobotics reports 20% revenue growth to $83.1 million for Q1 2026, driven by increased system sales and utilization.

PROCEPT BioRobotics reported a 43% revenue increase to $83.3 million in Q3 2025, driven by strong U.S. sales, though net losses continued at $21.4 million.

PROCEPT BioRobotics Corporation reported significant revenue growth and improved gross margins for the second quarter and first half of 2025, driven by increased system sales and utilization of its BPH treatment technology.

PROCEPT BioRobotics Corporation announces a 55% increase in revenue for Q1 2025, driven by growth in system sales and utilization of Aquablation therapy.

PROCEPT BioRobotics Corporation announced a 66% increase in revenue for the third quarter of 2024, driven by strong sales of its Aquablation therapy systems and consumables, and the launch of its next-generation HYDROS Robotic System.

PROCEPT BioRobotics Corporation announced a 70% increase in revenue for the six months ended June 30, 2024, driven by increased sales of their AquaBeam Robotic System and related consumables.

PROCEPT BioRobotics Corporation filed an amendment to its quarterly report to include details of two executive stock trading plans that were inadvertently omitted from the original filing.

PROCEPT BioRobotics Corporation reported a significant 83% increase in revenue for the first quarter of 2024, driven by higher sales of its AquaBeam Robotic System and related consumables.